PLASMID-IQ
Dead / Abandoned — Abandoned — failure to respond (as of 05 Jan 2026)
What this means for you
This application is over — abandoned 15 Dec 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 99128762
- Mark type
- Stylized text
- Filed
- 09 Apr 2025
- Abandoned
- 15 Dec 2025
- Attorney of record
- Joshua M. Gerben
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology
- Class 042 — Scientific and technological services: Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and · manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
Owner
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, King of Prussia, PA, US
Prosecution history
- 05 Jan 2026 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 05 Jan 2026 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 12 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Sept 2025 — NON-FINAL ACTION E-MAILED
- 12 Sept 2025 — NON-FINAL ACTION WRITTEN
- 05 Sept 2025 — ASSIGNED TO EXAMINER
- 20 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 22 Apr 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 22 Apr 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 22 Apr 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 09 Apr 2025 — NEW APPLICATION ENTERED
- 09 Apr 2025 — APPLICATION FILING RECEIPT MAILED